Upstream Bio, Inc. (UPB) Earnings Call Transcripts

Upstream Bio, Inc.'s Latest Earnings Call - June 10, 2026

In the Q2 2026 earnings call, Upstream Bio, Inc. (UPB:US) highlighted significant progress in its clinical programs, particularly with its lead asset, verekitug, targeting severe asthma and chronic rhinosinusitis with nasal polyps. The company reported promising Phase 2 results, including a 56% reduction in asthma exacerbations, and is on track to initiate Phase 3 trials in early 2027. Management maintained a strong cash position of nearly $300 million, sufficient to fund operations through 2027, while signaling a commitment to delivering a differentiated product with quarterly dosing and best-in-class efficacy. No changes to revenue or earnings guidance were provided, but the focus on clinical development could drive future stock performance.

Reported metrics

Guidance from management

Management did not provide specific revenue or earnings guidance but indicated strong confidence in the upcoming Phase 3 trials and the potential for a differentiated product launch.

What management said

Yes. So we're very fortunate that induction is not required here. We get very robust at 100% occupancy of [indiscernible] receptors within 2 weeks, actually sooner -- and so you do not need to load or do any kind of induction to get efficacy. And we've pretty clearly seen that. There is some element of dose response even at the first time point of measurement in our Phase 2 trials. And so for that reason, again, we'r...

What analysts pressed on

Analysts expressed concerns about the competitive landscape and the need for Upstream Bio to clearly differentiate its product in a crowded market. There were questions regarding the sustainability of efficacy and market access as new competitors emerge.

Main topics on the call

• Phase 2 Trial Results — Upstream Bio announced a 56% reduction in asthma exacerbations from its Phase 2 VALIANT trial, emphasizing the efficacy of its dosing regimen. CEO Rand Sutherland stated, "we were able to deliver a significant and clinic...
• Quarterly Dosing Advantage — The company is positioning verekitug with a unique quarterly dosing schedule, which could enhance patient compliance and market competitiveness. Sutherland noted, "when you start to extend the dosing interval, that actua...
• FDA Interaction and Phase 3 Plans — Management is engaging with the FDA to finalize plans for Phase 3 trials, expecting to dose the first patients in early 2027. Sutherland mentioned, "we expect to be done with those interactions by the end of Q3 of this y...
• Cash Position and Funding Strategy — Upstream Bio reported a cash position of nearly $300 million, which is expected to fund operations through 2027. Sutherland stated, "we are making heavy investments in device...critical for a successful launch."

Read the full Upstream Bio, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 3 Upstream Bio, Inc. earnings call transcripts on record, spanning January 13, 2025 to June 10, 2026. Based on this history, Upstream Bio, Inc. reports annually. The most recent call on file is dated June 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

UPB

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

3

First call

January 13, 2025

Most recent

June 10, 2026

Reporting cadence

annually